Skip to Content
Search Menu

PD-1 Inhibitors Have Shown Remarkable Efficacy

Hanne Hamre, Consultant, Medical Department, Akershus University Hospital, Norway, presented highlights and Norwegian perspectives on gastrointestinal cancer at the Norwegian Evening at ESMO 2024.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
Breast cancerESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynecological cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lung cancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynecological cancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanoma

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lung cancer
Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Livercancer Play the Video 04:57

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanoma
Back to top